Latest Conference Articles

New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.

Andrea Roman, PharmD, BCOP, discusses findings from a study investigating the benefits of remote oncology pharmacists.

Vitaly Margulis, MD, discusses the key takeaways and next steps of the Apa-RP study of apalutamide plus androgen deprivation therapy in patients with high-risk localized prostate cancer.

Vitaly Margulis, MD, reflects on the secondary end points findings and safety data from the Apa-RP study in high-risk localized prostate cancer.

Christopher Moertel, MD, discusses mirdametinib's mechanism of action and the implications of the phase 2b ReNeu trial of the agent in NF1-associated plexiform neurofibroma.

The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Vitaly Margulis, MD, discusses the significance of a 100% biochemical recurrence-free rate at 2 years, and what this means for patients with high-risk localized prostate cancer.

Vitaly Margulis, MD, discusses the Apa-RP study of adjuvant treatment consisting of apalutamide and androgen deprivation therapy in patients with high-risk localized prostate cancer.

Zanubrutinib plus venetoclax achieved a 100% overall response rate in patients with treatment-naive CLL/SLL harboring 17p deletions and/or TP53 mutations.

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.

MOST study shows high rates of disease progression in low/intermediate-risk myelofibrosis over 4 years, with the rate increasing over time. This offers valuable insight for a patient group with limited prior data.

Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.

Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

Aditya Bardia, MD, MPH, discusses results of a biomarker analysis of the TROPiCS-02 study of sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer presented at ASCO 2024.

William Dale, MD, PhD, discusses the unmet needs of older patients requiring cancer treatment.

Holly Pederson, MD, and Elisha Hughes, PhD, discuss the findings and implications of a study evaluating risk of triple-negative breast cancer for Black women presented at the 2024 ASCO Annual Meeting.

Joseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advanced non-small cell lung cancer.

The combination therapy showed consistent benefits across various subgroups, including those with poor-risk disease and higher PD-L1 expression.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.

Lenvatinib plus pembrolizumab delivered a significant benefit in time to disease progression in all organs vs sunitinib in advanced renal cell carcinoma.

Prophylactic treatment with tocilizumab shows promise for reducing a serious adverse effect in multiple myeloma treatment.

A promising new treatment option has emerged for patients with a specific type of gastrointestinal stromal tumor that has become resistant to standard therapy.

Frontline treatment with petosemtamab and pembrolizumab produced early clinical efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

The METIS trial of tumor treating fields for the treatment of brain metastases in patients with non–small cell lung cancer met its primary end point, showing a statistically significant improvement in time to intracranial progression.

The first safety run-in cohort of the MajesTEC-7 trial showed promising safety/efficacy results with teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma.

The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.

The combination of the adenovirus CAN-2409 and valacyclovir with continued immune checkpoint inhibitor therapy demonstrated favorable tolerability and induced a positive immune response.

A daratumumab-VRd–based regimen boosted the rate of MRD-negativity in patients with newly diagnosed, transplant-eligible multiple myeloma.